These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9732602)

  • 41. [Fat accumulation in the gastric submucosa secondary to chemotherapy. A case report documented by computerized tomography].
    Ferrozzi F; Schiavi A; Delnevo D; Campani R
    Radiol Med; 1997 Dec; 94(6):688-9. PubMed ID: 9524615
    [No Abstract]   [Full Text] [Related]  

  • 42. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
    Vasey PA
    J Clin Oncol; 2003 May; 21(10 Suppl):136s-144s. PubMed ID: 12743129
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation between in vitro drug response in the EDR assay and response to primary paclitaxel and cisplatin.
    DiSaia PJ
    Gynecol Oncol; 1999 Jul; 74(1):148-9; author reply 149-50. PubMed ID: 10385571
    [No Abstract]   [Full Text] [Related]  

  • 44. [Paclitaxel (Taxol)--drug of choice in ovarian cancer].
    Fishman A
    Harefuah; 1996 Apr; 130(8):557-60. PubMed ID: 8765885
    [No Abstract]   [Full Text] [Related]  

  • 45. ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit.
    Newman G
    Lancet; 2003 Oct; 362(9392):1333; author reply 1334. PubMed ID: 14575996
    [No Abstract]   [Full Text] [Related]  

  • 46. New therapy for ovarian cancer.
    Neijt JP
    N Engl J Med; 1996 Jan; 334(1):50-1. PubMed ID: 7494573
    [No Abstract]   [Full Text] [Related]  

  • 47. [Choice of first-line chemotherapy for advanced ovarian cancer].
    Tiuliandin SA
    Vopr Onkol; 1999; 45(4):350-4. PubMed ID: 10532090
    [No Abstract]   [Full Text] [Related]  

  • 48. ICON3 and chemotherapy for ovarian cancer.
    Pilotti S; Oggionni M; Böhm S; Pierotti MA; Zunino F
    Lancet; 2002 Dec 21-28; 360(9350):2087-8; author reply 2088. PubMed ID: 12504454
    [No Abstract]   [Full Text] [Related]  

  • 49. [Therapeutic strategies in advanced non-small cell bronchial cancers: combinations without platin drugs].
    Postmus P
    Rev Pneumol Clin; 2002 Nov; 58(5 Pt 2):3S48-50. PubMed ID: 12538936
    [No Abstract]   [Full Text] [Related]  

  • 50. [A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].
    Shimoya K; Kunishige I; Okuno Y; Hayashi S; Komura H; Arimoto Y; Otsuki Y
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):845-8. PubMed ID: 11432356
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination chemotherapy with paclitaxel and intraperitoneal cisplatin for ovarian cancer with disseminated lesions in the peritoneum and the diaphragm.
    Terauchi F; Moritake T; Yamamoto Y; Ogura H
    Int J Clin Oncol; 2002 Dec; 7(6):356-60. PubMed ID: 12494251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Comparative pharmaco-economic analysis of docetaxel with cisplatin and cyclophosphamide with cisplatin in first-line chemotherapy of advanced ovarian cancer].
    Gorbunova VA; Khokhlova SV; Komarova BP; Orel NF; Besova NS
    Vopr Onkol; 2002; 48(6):695-9. PubMed ID: 12530266
    [No Abstract]   [Full Text] [Related]  

  • 53. The treatment of ovarian cancer has reached new standards of care.
    ten Bokkel Huinink WW
    Eur J Cancer; 2000 Jan; 36(1):7-9. PubMed ID: 10741289
    [No Abstract]   [Full Text] [Related]  

  • 54. Current status of taxane and platinum-based chemotherapy in ovarian cancer.
    McGuire WP
    J Clin Oncol; 2003 May; 21(10 Suppl):133s-135s. PubMed ID: 12743128
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Confirmation of the "old" standard of care for ovarian cancer and a challenge.
    McGuire WP
    J Natl Cancer Inst; 2000 May; 92(9):674-5. PubMed ID: 10793094
    [No Abstract]   [Full Text] [Related]  

  • 56. Taxol: twenty years later, the story unfolds.
    Rowinsky EK; Donehower RC
    J Natl Cancer Inst; 1991 Dec; 83(24):1778-81. PubMed ID: 1683907
    [No Abstract]   [Full Text] [Related]  

  • 57. [Taxol in the treatment of ovarian neoplasm].
    Wang Y; Huang R; Huang H
    Zhonghua Fu Chan Ke Za Zhi; 1999 Jul; 34(7):439-41. PubMed ID: 11360659
    [No Abstract]   [Full Text] [Related]  

  • 58. Docetaxel combination produces 2-year survival advantage in NSCLC patients.
    Oncology (Williston Park); 2001 Dec; 15(12):1559, 1564. PubMed ID: 11780700
    [No Abstract]   [Full Text] [Related]  

  • 59. ICON3 and chemotherapy for ovarian cancer.
    Ozols RF; Markman M; Thigpen JT
    Lancet; 2002 Dec 21-28; 360(9350):2086-7; author reply 2088. PubMed ID: 12504453
    [No Abstract]   [Full Text] [Related]  

  • 60. Chemotherapy for ovarian cancer: an evidence-based approach.
    Geisler JP; Manahan KJ; Wiemann MC
    Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.